Refresh Intelligence Secures Tens of Millions in New Funding to Accelerate Mass Testing and Production of Medical-Grade Biosensors

VCBeat has learned that Shenzhen Refresh Smart Electronics Co., Ltd. (hereinafter referred to as “Refresh Smart”) recently closed a new round of financing amounting to tens of millions of yuan. The round was led by Leaguer Group, a subsidiary of Shenzhen Leaguer Science and Technology Innovation Co., Ltd. (hereinafter referred to as “Leaguer Sci-Tech,” stock code: 002243), with co-investment from the Shenzhen Government Guidance Fund, Shenzhen Leaguer Angel Venture Capital Partnership (Limited Partnership), Shenzhen Leaguer Hongxin Venture Capital Partnership (Limited Partnership), and Shenzhen Leaguer Angel Phase II Equity Investment Fund Partnership (Limited Partnership).

Following this round of financing, Leaguer Group has become the second-largest shareholder of Refresh Biosensor and has appointed senior executives to serve on its Board of Directors, laying a solid foundation for the company’s sustainable future development.

Shenzhen Refresh Biosensor Technology Co., Ltd., established in 2016, is a national high-tech enterprise dedicated to the research and development of miniaturized intelligent biosensor platforms. Under the leadership of Academician Zhang Xueji, the company has built China’s first electrochemical intelligent biosensing platform. Its core technologies include the self-developed MS02 biosignal processing chip, nanoscale microelectrode fabrication technology, biomembrane preparation and immobilization techniques, and adaptive intelligent sensing algorithms. The platform is widely applicable in various fields, including disease diagnosis and treatment, detection of chronic disease biomarkers, environmental monitoring, public health safety surveillance, and chemical defense monitoring. The company has established collaborations with over 300 university and research teams across China, and more than 50 biodetection teams are currently utilizing the BIOSYS platform system.

The successful completion of this funding round is of significant importance to the future development of Refresh Biosensor. The company will utilize these funds to enhance its experimental, process, and engineering platforms, expand its team, and accelerate the batch testing and mass production of its medical-grade biosensors.

Zhang Xueji is a Fellow of the American Institute for Medical and Biological Engineering,Fellow of the Royal Society of Chemistry,Foreign Academician of the Russian Academy of Engineering,Distinguished Professor appointed by the State,Chief Scientist of National Major Projects, Chief Scientist of National Key R&D Programs,Chairman of the China Bioassay and Monitoring Industry Innovation Alliance,Listed among Stanford University’s World’s Top 2% Scientists (2019, 2020),Serves as Editor-in-Chief of the Royal Society of Chemistry’s journal Sensors & Diagnostics (one of only four Chinese nationals to hold this editorial position worldwide to date),Currently serving as Vice President of Shenzhen University,2009–2019: Served as Deputy Director of the Academic Committee, Director of the Research Center for Bioengineering and Sensing Technology, Director of the Beijing Key Laboratory of Bioengineering and Sensing Technology, and Dean of the School of Chemical and Biological Engineering at the University of Science and Technology Beijing; and as Dean at Nanjing University of Science and Technology. 2008–2014: Deputy Director of the Department of Clinical Biochemistry and Distinguished Professor at the Chinese PLA General Hospital (301 Hospital). 1999–2012: Researcher, Chief Scientist, and Senior Vice President at World Precision Instruments (WPI).

Holds over 180 invention patents and has developed more than 30 industrialization technologies, which have been widely applied in over 100 countries worldwide. Has published nearly 500 papers in top-tier international academic journals, including Nature and Science subsidiaries, Chem. Rev., J. Am. Chem. Soc., Adv. Mater., ACS Nano, Chem. Commun., and Anal. Chem., with over 20,000 citations, and authored eight monographs in Chinese and English. Serves as Editor-in-Chief of RCS Sensors & Diagnostics and Am. J. Biomed. Sci., Associate Editor of Front. Biosci., and Editorial Board Member for 24 international journals.

Shenzhen Leaguer Innovation & Technology Co., Ltd. (abbreviated as “Leaguer,” stock code: 002243) is a key subsidiary of Shenzhen Investment Holdings Co., Ltd., a Fortune Global 500 company, and serves as the technology innovation service platform under the Shenzhen Tsinghua University Research Institute. As a national high-tech enterprise and an A-share listed company, Leaguer focuses on providing technology innovation services and cultivating tech-driven industries. It aims to build a conducive ecosystem for emerging industries by delivering top-tier innovation services and incubating leading-edge technological enterprises, striving to be a pioneer in the integrated development of innovation chains and industrial chains.

Lihe Sci-Tech Innovation operates 37 sci-tech innovation centers and industrial bases in core regions across China where innovation resources are highly concentrated, along with nine national-level business incubators and maker spaces. In collaboration with the Shenzhen Graduate School of Tsinghua University, it has established seven overseas innovation centers in North America, Europe, Israel, Japan, and other regions. The company has invested in nearly 500 high-tech enterprises, cumulatively incubated and served more than 3,100 companies, nurtured 26 listed companies, over 50 companies listed on the National Equities Exchange and Quotations (NEEQ), more than 300 National High-Tech Enterprises, and over 200 star sci-tech projects led by returning overseas talents.